Home/Pipeline/IMP761

IMP761

Autoimmune Diseases

Phase 1 (planned)Pre-clinical / IND-enabling

Key Facts

Indication

Autoimmune Diseases

Phase

Phase 1 (planned)

Status

Pre-clinical / IND-enabling

Company

Immutep

About Immutep

Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Inflammation & Immunology Programs	Pfizer	Phase 2/3	Active
ARGX-118	Argenx	Phase 1	Active
Adalimumab biosimilar (IBI303)	Innovent Biologics	Approved	Commercial
Hulio (Adalimumab)	Biocon	Approved	Commercial
Undisclosed ImmTAAI candidates	Immunocore	Preclinical	Research
BHV-1100 (IgG degrader)	Biohaven	Preclinical	Active
Bispecifics	Shattuck Labs	IND-Enabling	Preclinical
Preclinical Pipeline	Autolus Therapeutics	Pre-clinical	Active
FT839	Fate Therapeutics	Phase 1	Active